Given these findings, pivotal genes such as PHLDA1 and zinc finger protein 36-like 2 (ZFP36L2) may contribute to NAFLD through TLR, MAPK, and JAK-STAT pathways, representing potential therapeutic targets. This evidence concerns the gene SOAT1 and metabolic dysfunction-associated steatotic liver disease.